ViroGates A/S (CPH:VIRO)

Market Cap	115.56M +15.8%
Revenue (ttm)	8.11M +11.9%
Net Income	-12.39M
EPS	-1.60
Shares Out	9.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	954
Open	12.30
Previous Close	12.45
Day's Range	12.30 - 12.30
52-Week Range	5.98 - 17.40
Beta	0.71
RSI	49.31
Earnings Date	Mar 26, 2026

About ViroGates

ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic health issues, such as cardiovascular disease, type 2 diabetes, and cancer. The company’s product includes suPARnostic TurbiLatex, a latex particle-enhan...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2000
• Employees: 7
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: VIRO

Financial Performance

In 2024, ViroGates's revenue was 7.14 million, an increase of 2.22% compared to the previous year's 6.99 million. Losses were -14.35 million, 18.6% more than in 2023.